Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
about
sameAs
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre studyInterventions for guttate psoriasisSystemic pharmacological treatments for chronic plaque psoriasisAdverse effects of biologics: a network meta-analysis and Cochrane overviewMurine insulin growth factor-like (IGFL) and human IGFL1 proteins are induced in inflammatory skin conditions and bind to a novel tumor necrosis factor receptor family member, IGFLR1The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsGenome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysThe intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the gamesSerum TNF-alpha in psoriasis after treatment with propylthiouracil, an antithyroid thioureyleneTherapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesDermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in DiseaseOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyJakpot! New small molecules in autoimmune and inflammatory diseasesBiologics in dermatology: an integrated reviewAnti-TNF-alpha therapy and systemic vasculitis.Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.Emerging drugs for moderate-to-severe psoriasis.Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis.Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.Role of TNFalpha in early chemokine production and leukocyte infiltration into heart allografts.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment.Psoriasis (chronic plaque)Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Progress in understanding the immunopathogenesis of psoriasisAcute pustulosis of the legs in diverticulitis with sigmoid stenosis: an overlap between bowel-associated dermatosis-arthritis syndrome and pustular pyoderma gangrenosum.The 100 most cited psoriasis articles in clinical dermatologic journals, 1970 to 2012Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Overview of psoriasis.IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesisNovel immune-based therapies for psoriasis.The long-term efficacy and safety of new biological therapies for psoriasisBiologics in the management of psoriasis.Infliximab in the treatment of plaque type psoriasis.Cytokine therapy in dermatology.Cellular mechanisms of chronic cell-mediated allergic conjunctivitis.
P2860
Q22000875-691B6035-C59D-4563-A018-F786DA360B4AQ24188296-6194DCAD-720D-453E-9842-907F1192F691Q24188334-37802F36-0DE1-4E7B-944E-640D7B714CA0Q24234197-50A748CD-F65A-421A-A1FD-19255D4F7569Q24298540-9BB3DF5B-8E2B-4A75-9C20-490CFBB482D8Q24623195-B5B368AC-00EA-44D1-A801-4E63599EEF96Q24653432-EF89420D-0990-421A-98BA-3B5DDE1C1712Q24683018-DE161C96-687F-4596-B8ED-46423E4572EEQ24803476-E19B13C6-B7CA-4B89-8605-F295E9AC8490Q24806367-AB7A8AA3-F146-4952-BB94-EAAF4DC79FAFQ24816844-7CB07D4C-D3D9-4409-992C-4C254AD8AE82Q26801912-2640E40C-1857-467E-83B4-A1EECDE6FFBEQ26827714-8B96D06C-B1F4-44DA-9F34-D954C5B0247DQ27001957-17A84D40-1D09-42DE-869B-86AD92FB36BEQ27004638-788B09EA-546D-4F58-B539-856CA44C4B79Q27687590-A2CBB2E4-426D-44AF-84D0-FC24544A3DD4Q30251926-2769FFED-79CF-42FC-A3FD-731F4D9A83B2Q30984470-FE54BAAE-865E-4E8D-93D9-BEA91F908494Q33216851-07024F9C-D9E0-4617-A2C7-B84C07CB2F4FQ33288643-3AFDC796-560C-411D-B177-92975D90652FQ33358541-591204EF-F766-48D4-9C01-D8807C00406AQ33371653-74672049-7BE9-4DAF-A856-E9A2EEAF7FECQ33592507-1CDA8B25-D355-4E85-A04F-5767CA867333Q33625546-D80B22B3-8326-4934-95D5-7D7228CB0C89Q33632204-D386FB35-F7B1-46B6-967D-1647B14C0875Q34010557-CE53BC05-22CE-40CB-8A99-D307241CCB0FQ34112840-4F5E7CF3-8659-427D-9108-CBEA2D6FBECFQ34166896-0CD4E5F9-93C3-48B4-83B7-EB76677F4571Q34215381-77E0081B-B4A2-4354-9381-F5A41BA2DBF3Q34284078-547446BF-F55A-4FDF-AC41-C26EB04E908BQ34441450-F89D8A4D-235B-4894-A839-766BDC3117A0Q34476049-6E04A1E1-43AB-41A2-87D6-EF6764391228Q34551058-8420555F-D9CB-4149-8B1A-8574F0441959Q34577866-378785C5-4FA2-4A1D-B914-2834ADCBFFC8Q34609477-2E6CC11E-DF6A-4F51-903D-FC5B799FCAF2Q34613199-ADE815AB-884D-40CC-88EF-8400C5E70B12Q34620257-AE0E42C3-45B7-427F-A9E6-2CF1C47E70B5Q34620291-E86074B5-2174-40D4-B90C-C394343AF257Q34626999-C8552C28-1C6A-4ECF-ABA3-311AA7DB737DQ34669386-186B982D-0CEF-48E7-AEDB-4F4F6595A721
P2860
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
description
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique The Lancet
@fr
artículu científicu espublizáu en 2001
@ast
im Juni 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 9 June 2001)
@en
vedecký článok (publikovaný 2001/06/09)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/06/09)
@nl
наукова стаття, опублікована в червні 2001
@uk
name
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@ast
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@en
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@nl
type
label
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@ast
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@en
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@nl
prefLabel
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@ast
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@en
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@nl
P2093
P3181
P1433
P1476
Efficacy and safety of inflixi ...... psoriasis: a randomised trial
@en
P2093
A B Gottlieb
L D Mulcahy
L T Dooley
U Chaudhari
P304
P3181
P356
10.1016/S0140-6736(00)04954-0
P407
P577
2001-06-09T00:00:00Z